The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback